InVivoMab anti-mouse LFA-1α (CD11a) BE0005-1-R050mg from Bio X Cell | Biocompare.com

Supplier Images

InVivoMab anti-mouse LFA-1α (CD11a)

Be the first to write a review!

Citations:

Supplier Page from
Bio X Cell for
InVivoMab anti-mouse LFA-1α (CD11a)

Bio X Cell's InVivoMab anti-mouse LFA-1α (CD11a) is a Rat monoclonal antibody. The InVivoMab anti-mouse LFA-1α (CD11a) Antibody was generated using ITGAL as the antigen. It reacts with Mouse. This antibody has been shown to work in applications such as: In Vivo, and Block/Neutralize/Inhibit.

Description

Bio X Cell InVivoMAb anti-mouse LFA-1α (CD11a) Monoclonal Antibody has the following reported applications: in vivo LFA-1 neutralization. It features greater than 95% purity, ultra-low endotoxin levels, and are preservative, stabilizer, and carrier protein-free

Product Specs
ItemInVivoMab anti-mouse LFA-1α (CD11a)
CompanyBio X Cell
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberBE0005-1-R050mg
Quantity50 mg
Applicationsin vivo LFA-1 neutralization
ConcentrationLot specific,typically between 4-11 mg/ml
Conjugate/TagUnconjugated
ReactivityMouse
TargetLFA-1 alpha
IsotypeIgG2b
CloneFD441.8
Hostrat
NCBI Full Gene Nameintegrin alpha L
NCBI Gene Aliases(p180), Cd11a, LFA-1, LFA-1A, Ly-15, Ly-21
ClonalityMonoclonal
ImmunogenCloned CTL B18 cells
Antibody TypePrimary Antibody
Purity>95%, Determined by SDS-PAGE
FormatPBS, pH 7.0, Contains no stabilizers or preservatives
Research AreaCell Migration & Adhesion

Specifications/Features

Other available quantities: Available in 1, 5, 10, 25, 50, 100 mg and bulk sizes. Academic discount available.

Endotoxin: <2EU/mg (<0.002EU/µg), Determined by LAL gel clotting assay

Add to Compare List

Bio X Cell

Bio X Cell

39 Labombard Rd

Lebanon, NH 03766

United States

Phone: 1-866-787-3444

Email: customerservice@bxcell.com

Company Profile

Website: bioxcell.com

(1) Endogenous memory CD8 T cells directly mediate cardiac allograft rejectionAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant SurgeonsMarch 1, 2014Su CA, Iida S, Abe T, Fairchild RL.

(2) Endogenous memory CD8 T cells are activated within cardiac allografts without mediating rejectionAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant SurgeonsSeptember 1, 2013Setoguchi K, Hattori Y, Iida S, Baldwin WM 3rd, Fairchild RL.

(3) Pancreatic islet xenograft survival in mice is extended by a combination of alpha-1-antitrypsin and single-dose anti-CD4/CD8 therapyPloS oneJanuary 1, 2013Ashkenazi E, Baranovski BM, Shahaf G, Lewis EC.

(4) LFA-1 antagonism inhibits early infiltration of endogenous memory CD8 T cells into cardiac allografts and donor-reactive T cell primingAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant SurgeonsMay 1, 2011Setoguchi K, Schenk AD, Ishii D, Hattori Y, Baldwin WM 3rd, Tanabe K, Fairchild RL.

(5) Hapten application to the skin induces an inflammatory program directing hapten-primed effector CD8 T cell interaction with hapten-presenting endothelial cellsJournal of immunology (Baltimore, Md. : 1950)February 15, 2011Kish DD, Volokh N, Baldwin WM 3rd, Fairchild RL.

(6) Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent miceBloodDecember 24, 2009James SE, Orgun NN, Tedder TF, Shlomchik MJ, Jensen MC, Lin Y, Greenberg PD, Press OW.

Be the First to Write a Review!